Estrogen-like and tissue-selective effects of 7-methoxycoumarin from *Ficus umbellata* (Moraceae): an in vitro and in vivo study

Stéphane Zingue¹,²,³*, Thomas Michel⁴, Chantal Beatrice Magne Nde⁵, Amstrong Nang Njuh¹, Julia Cisilotto², Derek Tantoh Ndinteh³, Colin Clyne⁵, Xavier Fernandez⁴, Tânia Beatriz Creczynski-Pasa² and Dieudonné Njamen³,⁶*

**Abstract**

**Background:** *Ficus umbellata* is a medicinal plant previously shown to endow estrogenic properties. Its major component was isolated and characterized as 7-methoxycoumarin (MC). Noteworthy, coumarins and the respective active metabolite 7-hydroxycoumarin analogs have shown aromatase inhibitory activity, which is of particular interest in the treatment of estrogen-dependent cancers. The present work aimed at evaluating the estrogenic/antiestrogenic effects of MC in vitro and in vivo.

**Methods:** To do so, in vitro assays using E-screen and reporter gene were done. In vivo, a 3-day uterotrophic assay followed by a postmenopausal-like rat model to characterize MC as well as *F. umbellata* aqueous extract in ovariectomized Wistar rats was performed. The investigations focused on histological (vaginal and uterine epithelial height) and morphological (uterine wet weight, vagina stratification and cornification) endpoints, bone mass, biochemical parameters and lipid profile.

**Results:** MC induced a significant (*p* < 0.05) MCF-7 cell proliferation at a concentration of 0.1 μM, but did not inhibit the effect induced by estradiol in both E-screen and reporter gene assays. In vivo, MC treatment did not show an uterotrophic effect in both rat models used. However, MC (1 mg/kg) induced a significant increase (*p* < 0.01) of vaginal epithelial height. No significant change was observed with MC in abdominal fat weight, serum lipid levels and bone weight.

**Conclusion:** These results suggest that MC has a weak estrogenic activity in vitro and in vivo that accounts only in part to the estrogenicity of the whole plant extract. MC could be beneficial with regard to vagina dryness as it showed a tissue specific effect without exposing the uterus to a potential tumorigenic growth.

**Keywords:** *Ficus umbellata*, 7-methoxycoumarin, Phytoestrogens, E-screen assay, Uterotrophic assay

**Background**

Menopause is an inevitable phenomenon occurring naturally in women, characterized by a drop in estrogen levels and a definite cessation of menstruation [1]. It sets around the age of 50 years or following total ovariectomy and affects all women, independent of race and/or social strata [2]. Menopause marks the end of the reproductive life span of women and is often associated with a variety of physiological disorders like hot flushes, depressions and body weight increase. Although such disorders are not life threatening; the social life, as well as, the productivity of the women affected might be negatively impacted [3]. In the long term, estrogen deficiency affects bone density [4] and the cardiovascular system [5]. Hormone replacement therapy (HRT) has therefore been proposed as a solution to postmenopausal symptoms. It is especially effective for the treatment of severe vasomotor and estrogen-deficiency mucosal symptoms, as well as in slowing down the rate of bone demineralization [6]. However, Women’s Health Initiative and the British Million Women Studies

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
reported that HRT is associated with higher incidence of mammary cancers and arteriosclerotic complications such as heart attack and stroke [7]. This raises questions about the exclusive beneficial effects of HRT [8]. Emerging evidence tends to support the short-term use of HRT for severe menopausal symptoms and its avoidance for long-term prophylaxis [9]. Many menopausal women have therefore turned to non-hormonal therapies [10]. Nowadays, there is the vigorous promotion of plant-derived phytoestrogens in a bid to seek for alternatives to HRT. The structural similarity of phytoestrogens to endogenous estradiol permits them to bind and activate estrogen receptors in mammals. The considerable scientific effort is being placed in a search for phytoestrogens that could exhibit optimal estrogenic activity, i.e. with positive effects on bone health while having little effect on uterine or breast tissues [11]. *Ficus umbellata* Vahl (Moraceae) is a tree that grows in tropical areas; commonly called “Tol” in “Ewondo” or “Mewed” in “Guiziga”. The bark of *F. umbellata* is used to treat menopause related physiological disorders [12]. In our previous work, aqueous and methanol extracts of *F. umbellata* transactivated the Estrogen Receptor α (ERα) in a reporter gene assay and induced significant estrogen-like effects on estrogen target organs (uterus, vagina and mammary gland) in rats. Furthermore, it significantly decreased the frequency of hot flushes in experimental rats. Its major component was isolated and characterized as 7-methoxycoumarin (MC) [13]. Coumarins consist of a group of compounds characterized by 1,2-benzopyrone or benzopyran-2-ones, which are extensively studied. A number of coumarins exhibit interesting pharmacological activities and are therefore of therapeutic use [14]. Indeed, some coumarins and their active metabolite 7-hydroxycoumarin analogs have shown aromatase inhibitory activity, which is of particular interest in the treatment of estrogen-dependent cancers (ovaries, uterus and breast cancers) [15, 16]. Preliminary in vitro tests performed with this compound showed that it failed to transactivate ERα and ERβ in a reporter gene assay [13]. In the present study, in depth in vitro estrogenic assay and a 3-day uterotrophic assay in ovariectomized adult rats were performed to characterize the effects of MC. Thereafter, the effects of MC as well as *F. umbellata* aqueous extract were evaluated using a postmenopausal-like rat model.

**Methods**

**Chemicals**

Mass Spectroscopy (MS) grade methanol, acetonitrile (ACN), water and formic acid (FA) were purchased from Sigma-Aldrich (Saint-Quentin Fallavier, France). Fetal bovine serum (FBS) and antibiotics were purchased from GIBCO (Grand Island, NY). The 17β-estradiol benzoate [(Estr-1,3,5(10)-trien-3,16α,17β-triol); purity ≥98%] was obtained from Sigma-Aldrich (Hamburg, Germany). Estradiol valerate (Proginova® 2 mg) was purchased from DELPHARM (Lille, France). The 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethane sulfonic acid (HEPES, purity ≥99.5%) was purchased from Ludwig Biotecnologia Ltda (Alvorada, RS, Brazil). Trypan blue, Sulforodamine B, Serum Replacement 2 and cell culture mediums were purchased from Sigma-Aldrich (St. Louis, MO, USA). Genistein was obtained from “Extrasynthese” (Genay, France).

**Plant material and preparation of *F. umbellata* extracts**

Stem barks of *F. umbellata* were harvested in Yaounde (Centre region, Cameroon) in September 2013. This botanical sample was authenticated by Mr. Victor Nana, a botanist at the National Herbarium of Cameroon (HNC) by comparison to the specimens deposited under the voucher number 99/HNC. After drying under the shade in an aerated place for 2 weeks, the well-dried stem barks of *F. umbellata* were pulverized by electronic grinding. Then, 2 kg of powder was macerated in water at room temperature (5 L of solvent × 3, 48 h per extraction). Thereafter solutions were filtered through Whatman paper N°4 and evaporated using an oven with ventilation (40 °C, during 48 h) to yield 229.8 g of aqueous crude extract. Likewise, 2.7 kg of the powder was macerated in 95% methanol at room temperature (5 L of solvent × 3, 48 h per extraction). The combined solutions were evaporated under reduced pressure (337 mbar at 40 °C) using a rotary evaporator to yield 162 g of a methanol crude extract (MeOH).

**Isolation of 7-methoxycoumarin (MC)**

The different Ultra Performance Liquid Chromatography (UPLC) chromatograms of *F. umbellata* aqueous and methanol extracts showed that MC is their major compound. The MC was then isolated after a bio-guided fractionation of *F. umbellata* methanol extract as previously reported [13]. The physicochemical properties of MC are summarized in Table 1.

**UPLC-ESI-MS analyses of *F. umbellata***

Analyses of *F. umbellata* extracts were performed by UPLC-high resolution electrospray ionization MS (HRE- SIMS) on an ACQUITY UPLC™/Xevo™ G2 QTof (Waters, USA). All separations were performed on an Acquity UPLC BEH C-18 column (100 mm × 2.1 mm I.D., 1.7 μm) at 25 °C with a flow rate of 0.400 mL/min. A guard column (5 mm × 2.1 mm, 1.7 μm) with the same stationary phase was placed before the column. The mobile phase consisted of water +0.1% FA (solvent A) and ACN + 0.1% FA (solvent B) and was used in multistep gradient mode. The gradient was operated as
follows: 0–1 min, 5% B; 1–9 min, 5–40% B; 9–15 min, 40–100% B. The injection loop was set at 0.5 μL and 10 °C was used as the sample manager temperature. The standard Acquity PDA module was used for online UV detection in the range of 200–700 nm range, with a resolution of 1.2 nm and a sampling rate of 10 spectra/s. The HRMS and HRMS/MS data were acquired in negative mode with a mass range of 100–1500 m/z. The ESI conditions operated were as follows: source temperature 120 °C, desolvation temperature 500 °C; capillary voltage 1.5 KV, cone voltage 10 V. Nitrogen was used as a cone (10 L/Hr) and desolvation gases (1000 L/Hr). Lockspray flow rate was set at 20 μL/min and Lockspray capillary at 2.5 KV. For the HRMS/MS acquisitions, a method including the detection (full scan) and fragmentation of the most intense peaks per scan was used. The collision energy varied from 10 to 35 V.

**In vitro experiments**

**Cell line systems**
The MCF-7 – human ER-positive breast adenocarcinoma cell line was obtained from the Rio de Janeiro Cell Bank (Federal University of Rio de Janeiro, Brazil). Human Embryonic Kidney 293 T (HEK 293 T) cell line expressing the SV40 large T-antigen was obtained from ATCC (The Global Bioresource Center, Australia). The luciferase reporter assay, ERα and ERβ expression plasmids were kindly provided by Dr. Simon Chu (Hudson Institute of Medical Research, Australia). Cells were transfected using Lipofectamine Reagent obtained from Invitrogen (Sydney, Australia).

**Cell culture**
MCF-7 cells were cultured in RPMI-1640 medium supplemented with fetal bovine serum (FBS) 10%. Cell cultures were also supplemented with penicillin 100 U/mL, streptomycin 100 μg/mL and HEPES 10 mM. They were maintained at 37 °C in a CO2 5% humidified atmosphere and pH 7.4. Every 2 days, cells were passaged by removing 90% of the supernatant and replaced by fresh medium. Viable cells (a minimum of 95%) were checked at the beginning of the experiment by Trypan Blue dye exclusion test.

HEK293T cells were routinely maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with sodium pyruvate 1 mM, glutamine 4 mM, 4.5 g/l of glucose, and fetal bovine serum 10% in a humidified atmosphere at 37 °C in a CO2 5%. Prior to transfection, the media was replaced by the 5% Charcoal Stripped Serum DMEM phenol free. Cells were then seeded at the density of 50,000 per well in a 24 well-plate format. The next day, they were transfected with appropriate plasmids in the starving media O/N and treated in the same media.

**E-screen assay**
The E-screen MCF-7 cells proliferation assay was performed as described by Resende et al. [171]. Briefly, cells were trypsinized and seeded in 24-well plates at an initial concentration of 5 × 10^4 cells per well in RPMI supplemented with FBS 10%. After 24 h of incubation (37 °C, CO2 5%) to permit their adhesion, cells were washed with phosphate-buffered saline-PBS (NaCl 137 mM; KCl 2.7 mM; Na2HPO4 10 mM; KH2PO4 1.8 mM, pH 7.4) and the Serum Replacement 2 (0.5×) supplemented phenol-red free RPMI was substituted for the seeding medium. A stock solution of 7-methoxycoumarin 100 mM prepared in DMSO was then added to the experimental medium in order to reach concentrations from 1 × 10^{-8} to 1 × 10^{-5} M. The DMSO concentration of 0.01% was fixed based on the final volume on different wells. For antiestrogenic evaluation, before cell incubation, 17β-estradiol 1 × 10^{-8} M was added to the wells. Cells treated with DMSO (0.01%) and FBS 10% in RPMI served as solvent and medium controls, respectively. The assay was stopped after 144 h by removing the medium from the wells, fixing the cells with cold trichloracetic acid 10% and incubated at 4 °C for 1 h. Thereafter, cells were washed four times with tap water and dried. Cells were stained for 30 min with sulforhodamine-B (SRB) 0.057% (w/v) which was dissolved in 1% acetic acid, rinsed four times with acetic acid 1% and air-dried. Bound dye was solubilized with

### Table 1 General information on 7-methoxycoumarin isolated from *F. umbellata*

| Code and names | Crystal color | Structure, molecular weight and formula |
|---------------|--------------|----------------------------------------|
| 7-methoxycoumarin | White | ![Diagram](attachment:structure.png) |
| Methylumbelliferone | | |
| 7-methoxy-2H-chromen-2-one | | |
| MC | | Molecular weight = 176.1 M  
Molecular formula = C10H8O3 |
Tris base 10 mM (pH 10.5) in a shaker. Finally, aliquots were read in a Biotek EL800 absorbance reader (Winooski, USA) at 510 nm. The results related to estrogenic activity were expressed as mean ± standard error of the mean (SEM) of the proliferative effect (PE), which was calculated according to Schiliro’ et al. [18]: 

\[
PE = \frac{max \ cell \ number \ of \ sample/cell \ number \ of \ DMSO \ control}
\]

The estrogenic activity of a sample was determined as the relative proliferative effect (RPE%). The RPE compares the maximum proliferation induced by a sample with that induced by 17β-estradiol: 

\[
RPE\% = \frac{PE \ for \ sample/PE \ for \ 17β-estradiol} \times 100
\]

**Transfections and luciferase assays**

As far as the MC failed to transactivate estrogen receptors α and β, in the Human Embryonic Kidney 293 T cell line (HEK293T) transiently transfected with adequate plasmids using Lipofectamine Reagent as thoroughly described by Zingue et al. [13]. The present experiment was aimed to evaluate the possible antiestrogenic effects of this compound in the same cell system and at the concentrations used in our previous study [13]. Briefly, HEK293T cells were transiently transfected with 200 ng of estrogen α-receptor plasmid or estrogen β-receptor expression plasmid, together with the double estrogen response element (ERE) and a luciferase reporter [250 ng (ERE)2-tk-Luc] plasmid kindly provided by Dr. Simon Chu (Hudson Institute of Medical Research, Melbourne, Australia) and β-galactosidase reporter plasmid using Lipofectamine Reagent (Invitrogen, Mulgrave, Australia). They were then treated with different concentrations (1 × 10⁻⁸ to 1 × 10⁻⁵ M) of the MC in combination with E2 for 24 h prepared from a 100 mM stock dissolved in 70% Ethanol. E2 alone or in combination with ICI 182,780 were used as positive control. Reporter gene assays in HEK293T-ERα cells and HEK293T-ERβ cells were done using a commercial kit (Promega, Melbourne, Australia) according to the manufacturer’s instructions. Luciferase activity was measured and normalized toward β-galactosidase activity determined by using the 2-nitrophenyl b-d-galactopyranoside (ONPG) method (Sigma-Aldrich, Sydney, Australia).

**In vivo experiments**

**Animals**

Healthy juvenile female Wistar rats aged 3 months (~150 g) were obtained from the breeding facility of the Laboratory of Animal Physiology, University of Yaunde I (Cameroon). Animals were housed in clean plastic cages at room temperature (around 25 °C) under natural illumination (approx. 12 h light/dark). The animals had free access to a standard soy-free rat chow (Table 2) and water.

### Table 2 Rat chow composition

| Content                     | Mass (g/100 g) | Percentage |
|-----------------------------|----------------|------------|
| Corn                        | 36.467         | 36.5%      |
| Bone flour                  | 14.587         | 14.6%      |
| Wheat                       | 36.467         | 36.5%      |
| Fish flour                  | 4.862          | 4.9%       |
| Crushed palm kernel         | 7.293          | 7.3%       |
| Sodium chloride (NaCl)      | 0.303          | 0.3%       |
| Vitamin complex (Olivitazol®)| 0.018          | 0.02%      |

**Ethical consideration**

The housing of animals and all experiments were approved by the Cameroon Institutional National Ethic Committee, which adopted all procedures recommended by the European Union on the protection of animals used for scientific purposes (CEE Council 86/609; Reg. no. FWA-IRD 0001954).

**Determination of doses**

For the in vivo experiments, estradiol benzoate (E2B) and faslodex were administered subcutaneously at the doses of 2 μg/kg and 300 μg/kg, respectively as described by Zingue et al. [19]. The well-known phytoestrogen genistein was administered at a dose of 10 mg/kg [20]. Based on the amount of the 7-methoxycoumarin isolated from *F. umbellata* methanol extract, the quantity contained in the optimal dose (200 mg/kg) of this extract was found to be around 1 mg/kg. This dose was framed between the lowest dose of 0.1 mg/kg and the highest dose of 10 mg/kg.

**The 3-day uterotrophic assay**

In this part of the work (Fig. 1a), 50 female Wistar rats aged 2.5 months were bilaterally ovariectomized (OVX) using the dorsal approach under Diazepam and ketamine anesthesia (respectively 10 mg/kg and 50 mg/kg BW; i.p.). After 14 days of endogenous hormonal decline, animals were randomly allocated into 10 groups of five animals each (*n* = 5). Group I received vehicle (corn oil) and served as negative control. Group II received estradiol Benzoate (E2B) as standard drug at the dose of 2 μg/kg per day. Group III received estradiol Benzoate (E2B, 2 μg/kg) co-administered with the pure antiestrogen faslodex (ICI 182,780; 300 μg/kg). Group IV received genistein as phytoestrogen control at the dose of 10 mg/kg. Group V, VI and VII received 7-methoxycoumarin (MC) at doses of 0.1, 1 and 10 mg/kg, respectively. The remaining three groups (group VIII, IX and X) were co-treated with estradiol Benzoate (E2B, 2 μg/kg) and MC at doses of 0.1, 1 and 10 mg/kg, respectively. Estradiol benzoate, faslodex (ICI, 182,780), MC and genistein were dissolved in vehicle (corn oil).
All treatments were given by subcutaneous route (0.3 mL/150 g) for 3 consecutive days. Twenty-four hours after the last injection, animals were euthanized. The uterine wet weight, uterine and vaginal epithelial heights were assessed as described before by Zingue et al. [13].

**Postmenopausal-like rat model**

Five animals were sham-operated under Diazepam and ketamine anesthesia (respectively 10 mg/kg and 50 mg/kg BW; i.p.) and 25 other rats were bilaterally ovariectomized as described above (Fig. 1b). Eighty-four (84) days after ovariectomy to the onset of postmenopausal-like conditions in rat [21], animals were randomly distributed into six groups of 5 animals each ($n = 5$). Group I (SHAM) was sham operated rats and received distilled water. Group II to VI were ovariectomized rats treated as follows: Group II received distilled water as a negative control (OVX). Group III served as positive control and received estradiol valerate (1 mg/kg). Group IV received the MC at the dose of 1 mg/kg and remaining Group V and VI the *F. umbellata* aqueous extract at the doses of 50 and 200 mg/kg. All substances were dissolved in distilled water and administered by oral gavage route (2 mL/250 g) for 21 consecutive days. Throughout the experiment, animals were weighed once every week in order to determine the weight gain. Twenty-four hours after the last treatment, animals were euthanized and blood samples were collected and centrifuged at 3000×g for 15 min and serums were stored at −4 °C for further analysis. The uterine, vagina, mammary gland, abdomininal fat, liver, lungs, kidneys, adrenergic gland, femur and tibia were collected, cleaned of the superficial fatty layer and weighed. Femurs were dried at 110 °C for 12 h and weighed. All collected organs were fixed in 10% formalin for histological analysis.

**Histological analysis**

The histomorphology of the uterus, vagina, femur, liver, lungs and kidneys was performed from 5-μm sections of paraffin-embedded tissues following hematoxylin-eosin staining. Organs were photographed at 40 × magnification using the complete Zeiss equipment consisting of a microscope Axioskop 40 connected to a computer where the image was transferred, and analyzed with the MRGrab1.0 and Axio Vision 3.1, both Zeiss (Hallbermoos, Germany) software’s.

**Biochemical analysis**

Total-cholesterol, HDL-cholesterol, and triglycerides blood levels were determined enzymatically using reagent-kits purchased from Biolabo (France). The artherogenic index was calculated as total cholesterol on HDL cholesterol.

**Statistical analysis**

Results were presented as means ± standard error of the mean (SEM). In vitro experiments were performed in triplicates and repeated three times. Data analysis was performed with GraphPad Prism 6.0 software, using the ANOVA test followed by the Dunnett’s post hoc test to compare each treatment with a control group. Differences were considered significant at a probability level of 5% ($p < 0.05$).
Results
Phytochemical analysis of *F. umbellata* extract by UHPLC-HRMS/MS

A qualitative analysis of the *F. umbellata* extract was performed using UHPLC-HRMS/MS by electrospray ionization in negative mode. Compound identification was based on their retention time, elemental composition (EC), monoisotopic mass of the pseudomolecular ion (m/z), RDBeq values, and their major HRMS/MS fragments. All well resolved peaks in TIC was selected and possible EC were calculated. The compounds detected in the methanol extract are summarized in Additional file 1: Table S1 and only eventual estrogenic compounds have been depicted in Fig. 2. A total of 40 secondary metabolites were detected in the active extract of *F. umbellata* belonging to various chemical classes including hydroxybenzoic acids, hydroxycinnamic acids, coumarins, flavonoids and triterpene derivatives. Among them, 4 were identified or putatively characterized based on the dereplication strategy as eventual estrogenic compounds (Fig. 2). In this study, we confirmed the presence of 7-methoxycoumarin at m/z 175.0384 (Rt 6.0 min) already described in our previous work as the major component of *F. umbellata* [13], but also other coumarins such as dihydroxycoumarin at m/z 177.0184 (Rt 6.35 min) and prenyl-7-hydroxycoumarin at 229.0865 (Rt 9.01 min), Genistein (Rt 6.55 min, m/z 269.0446) and biochanin A (Rt 8.89 min, m/z 283.0607) already described in *F. carica* [22] were identified based on their MS/MS fragmentation patterns.

In vitro estrogenicity assessment

*E*-screen assay

In the Fig. 3a is shown a significant ($p < 0.001$) increase by 17-$\beta$ estradiol-induced in MCF-7 cells proliferation. The MC induced a significant ($p < 0.05$) MCF-7 cells proliferation only at the concentration of 0.1 $\mu$M as compared to DMSO control. No antiestrogenic activity was noted with all tested concentrations of MC in this assay.

Transactivation assay

The Fig. 3b and c showed that MC failed to inhibit the transactivation of ER$\alpha$ as well as ER$\beta$ induced by estradiol (E2). No significant change was observed with the co-treatment MC plus estradiol, suggesting that it has no antiestrogenic properties.

In vivo estrogenicity assessment

Effects on uterus

Figure 4 depicts that E2B induced a significant ($p < 0.001$) increase in the uterine wet weight as well as in the uterine epithelial height as compared to the OVX group. The pure antiestrogen faslodex significantly ($p < 0.001$) abolished the effects of E2B. Genistein, a well characterized phytoestrogen did not exert significant changes in uterine wet weight whereas, it induced a significant ($p < 0.05$) increase
in uterine epithelial height. No estrogenic effects were noted following the treatment with MC in the uterus at all tested doses. However, MC (0.1 mg/kg) induced a significant \( p < 0.05 \) decrease in the endometrium height when co-administered with E2B (Fig 4b).

### Effects on vagina

The effects observed following a 3-day treatment with different substances on the vagina are shown in Fig. 5. There was a significant increase in the vaginal epithelium height with E2B \( (p < 0.001) \) and genistein \( (p < 0.01) \) treatments, while co-treatment of the E2B and Faslodex significantly \( (p < 0.001) \) abolished the effects of estradiol on vaginal epithelium. The MC induced a significant increase \( (p < 0.01) \) in the vaginal epithelium height only at the dose of 1 mg/kg. No antiestrogenic activity was noted on vagina epithelium with MC.

### Effect of 7-methoxycoumarin and *F. umbellata* extract on postmenopausal symptoms

#### Effects on estrogen target organs

Effects of different treatments on estrogen target organs in postmenopausal-like conditions are summarized in Table 3. An 84-day post-ovariectomy induced a significant \( (p < 0.001) \) reduction in uterine wet weight, uterine and vaginal epithelial heights. E2V significantly \( (p < 0.001) \) increased the uterine wet weight as well as uterine and vaginal epithelial heights. There was no change on the uterine wet weight as well as the uterine epithelial height upon administration of *F. umbellata* aqueous extract. Interestingly, *F. umbellata* aqueous extract at both doses (50 and 200 mg/kg) as well as MC (1 mg/kg) significantly \( (p < 0.01) \) increased vaginal epithelial height as compared to control OVX (Table 3).

#### Fasting serum lipids

A slight but significant \( (p < 0.05) \) increase in fasting serum total cholesterol levels and triglycerides levels (Table 3) was observed in animals of OVX group compared to sham operated animals, while the HDL-cholesterol levels significantly \( (p < 0.01) \) decreased (Table 3). Hence, the atherogenic risk, calculated as the ratio of total cholesterol to HDL-cholesterol increased. The E2V group (1 mg/kg BW) significantly \( (p < 0.05) \) decreased triglycerides and total cholesterol levels, while it increased HDL-cholesterol level after 21 days of treatment. *F. umbellata* aqueous extract at the dose of 200 mg/kg BW on the other hand decreased total cholesterol and increased HDL-cholesterol levels as compared to the control. Moreover, the atherogenic risk was significantly decreased by E2V and the methanol extract of *F. umbellata* at the dose of 200 mg/kg BW. The 7-methoxycoumarin did not induce significant changes in fasting serum lipids (Table 3).

### Effects on body weight and relative organ weights

Body weight of all animals increased after the ovariec- tomy. Table 4 displays only the variation of body weight during the period of treatment. A significant \( (p < 0.05) \) increase in the body weight between the onsets of
treatment until the end with OVX group was noted. A slight decrease in body weight was noted with estradiol treatment (E2V). *F. umbellata* aqueous extract prevented increase in the body weight. No change was noted in relative weights of liver, lungs, kidneys and adrenergic glands (Table 4). However, a significant increase in femur wet ($p < 0.01$) and dried ($p < 0.001$) weights as well as in tibia wet weight ($p < 0.01$) with *F. umbellata* treatment at both doses was noted. In addition, a significant decrease of abdominal fat was observed in rats treated with E2V ($p < 0.01$) and *F. umbellata* aqueous extract at the dose of 200 mg/kg ($p < 0.05$).

**Effects on the microarchitecture of some organs**

No alterations in the microarchitecture of liver, lungs and kidneys were noted in this work (Additional file 1: Figure S2). However, the femur microarchitecture of OVX rats showed bone marrow disparities into the trabecular network. E2V and *F. umbellata* aqueous extract (200 mg/kg) treatments prevented bone resorption, evidenced by the inhibition of bone marrow loss into the trabecular network. MC did not induce significant change in the bone microarchitecture.

**Discussion**

Coumarins comprise of compounds characterized by 1,2-benzopyrone or benzopyran-2-ones, which are extensively studied. Many valuable biological activities have been assigned to coumarins [14]. The 7-methoxycoumarin (MC) used in this study was isolated as the major component of *F. umbellata*. This compound failed to transactivate estrogen receptors (ERα and ERβ) in vitro in our previous work [13]. However, it was observed in this study that MC induced a significant proliferation in MCF-7 cells in an E-screen assay at the concentration of 0.1 μM, while it did not alter MCF-7 cells proliferation when co-administered with estradiol at all tested concentrations. In
addition, MC did not alter ERα and ERβ stably transfected in HEK293T cells when co-administered with estradiol. These observations are consistent with those obtained in the E-screen assay and suggest that MC has a weak estrogen-like effect but no antiestrogenic effects in vitro. The E-screen assay measures cell proliferation, which is well known as a hallmark of estrogen-like activity [23]. The fact that MC induced MCF-7 cell proliferation and failed to transactivate ERs in vitro raises two hypotheses. On one hand, MC might induce its estrogenicity via a non-genomic pathway, since MCF-7 cell proliferation involves both genomic and non-genomic pathways [18]. On the other hand, this compound might undergo hydroxylation by MCF-7 cell enzymes and then bind to ERs such as 6-hydroxycoumarin, which is well known to transactivate ERs [24]. In vivo results show that a 3-day
treatment with MC neither induced estrogenic nor antiestrogenic effects on the uterus. However, a slight but not significant increase in endometrial thickness was observed in vivo, which is consistent with the weak estrogenicity observed with MC in vitro. The uterus and mammary glands express much ERs than ERβ [25], which may explain the above observations. These results suggest that MC is not responsible for the observed estrogenic effects of F. umbellata extract on the uterus [13]. Furthermore, MC induced a significant increase in vaginal epithelial height in ovariectomized rats at the dose of 1 mg/kg after a 3-day treatment. In addition, no estrogenic activity was noted in the uterus after 21 consecutive days of treatment with this compound in the postmenopausal-like rat model, while it induced a significant increase in vaginal epithelial height as it did in the 3-day uterotrophic assay. These results point out a tissue-selective activity for this compound and strengthen our hypothesis that MC is responsible only in part for the estrogenic activity of F. umbellata. 6-hydroxycoumarin, Genistein and Biochanin A detected in F. umbellata extract by UPLC-MS in this study are well known phytoestrogens, that might account for its effects on the uterus.

After 21 days of treatment with MC and F. umbellata aqueous extract, no significant changes were noticed on the relative weights of liver, lungs, kidneys, and adrenal glands as well as in the microarchitecture of the liver, lungs and kidneys; suggesting that these substances are weakly toxic. These observations corroborate our previous finding that the LD50 of F. umbellata is more than 5000 mg/kg [13]; thus supporting its use in the traditional medicine. Interestingly, a significant increase in femur wet and dry weights as well as in the tibia wet weight with F. umbellata aqueous extract was observed at the dose of 200 mg/kg, while MC failed to induce such effects. Since postmenopausal osteoporosis is a worldwide health problem with a high prevalence [26], these results encourage the exploration of the antosteoporotic potential of F. umbellata extract. Preventive effects of phytoestrogens on postmenopausal osteoporosis are well known [27]. As far as F. umbellata transactivated ERs in vitro, its components might bind to ERs, which have been localized in osteoblasts and osteoclasts and limit bone reabsorption by inhibiting osteoclasts [28]. It seems that MC does not contribute to the effects of F. umbellata aqueous extract in bones.

Estrogen deficiency is associated with dyslipidemia, a major cause of increased risk of developing cardiovascular disease [29]. In this study ovariectomy induced a significant variation of serum total cholesterol levels. Following treatment, E2V decreased the serum total cholesterol levels compared to the negative control (OVX). E2 has been shown to inhibit the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase in cholesterol biosynthesis as well as the rate-limiting enzyme in the cholesterol synthesis de novo [30], hence reducing the synthesis of cholesterol. Scientific reports point out the evidence that this effect on cholesterol metabolism might be mediated by ERs [31]. Conversely, MC failed to change fasting serum lipids. However, F. umbellata aqueous extract exhibited estrogen-like effects by decreasing fasting serum total cholesterol and increase serum HDL cholesterol levels at a dose of 200 mg/kg. Atherogenic index was used as an indicator of cardiovascular risks. The increase in HDL-Cholesterol levels in E2V-treated animals observed in this work is in accordance with other reports, which demonstrated an increase in HDL-Cholesterol levels following estrogen treatment in humans [32, 33]. Results on atherogenic risks showed that F. umbellata but not MC has

| Items                        | SHAM          | OVX           | E2V         | FU 50         | FU 200        | MC           |
|-----------------------------|---------------|---------------|-------------|---------------|---------------|--------------|
| Estrogen target organs      |               |               |             |               |               |              |
| Uterine wet weight (mg/kg)  | 1921.36±185.26| 356.9±19.05### | 1288.42±136.9*** | 546.12±44.24 | 349.69±7.69 | 409.83±15.81 |
| Uterine epithelial height (µm) | 6.71±0.36    | 3.06±0.16### | 5.27±0.15*** | 3.6±0.37     | 3.8±0.18     | 3.39±0.20    |
| Vaginal epithelial height (µm) | 19.06±0.11   | 2.54±0.56### | 14.25±0.55*** | 6.24±0.20** | 7.8±0.01** | 8.56±1.39### |
| Lipids profile              |               |               |             |               |               |              |
| Total cholesterol level (mg/dL) | 67.92±6.27 | 93.9±2.29### | 56.98±11.27* | 83.01±10.27 | 56.53±4.99* | 79.24±11.67 |
| Triglycerides levels (mg/dL) | 47.96±3.75   | 62.96±7.35*   | 44.66±2.02* | 63.01±6.46  | 49.48±1.67  | 56.08±4.26  |
| HDL-Cholesterol level (mg/dL) | 46.62±0.91  | 44.91±0.34*    | 45.94±0.54* | 45.1±0.38   | 45.60±0.66* | 45.33±0.44  |
| Atherogenic risk            | 1.28±0.20    | 1.63±0.15     | 1.19±0.15*  | 1.84±0.22   | 1.19±0.21*  | 1.69±0.22   |

SHAM = Sham operated rats treated with vehicle as normal control; OVX = Ovariectomized rats treated with vehicle as negative control; E2V = Ovariectomized rats treated with estradiol valerate at the dose of 1 mg/kg BW; FU 50 and 200 = Ovariectomized rats treated with F. umbellata aqueous extract at the doses of 50 and 200 mg/kg BW, respectively; MC = Ovariectomized rats treated with 7-methoxycoumarin at the dose of 1 mg/kg BW. *p <0.05, **p < 0.01, ***p <0.001 as compared to SHAM group. *p <0.05, **p < 0.01, ***p <0.001 as compared to OVX group.
| Organs                  | Ovariectomized rats | Ovariectomized rats | Ovariectomized rats | Ovariectomized rats | Ovariectomized rats | Ovariectomized rats |
|------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|                        | SHAM                | OVX                 | E2V                 | FU 50               | FU 200              | MC                  |
| Body weight (g)        |                     |                     |                     |                     |                     |                     |
| Initial                | 166.11 ± 8.74       | 196.21 ± 5.96       | 223.4 ± 11.16       | 221.4 ± 9.99        | 227.2 ± 6.37        | 217.4 ± 9.63        |
| Final                  | 170.12 ± 9.07       | 228.25 ± 9.87*      | 227.8 ± 10.38       | 213.1 ± 12.30       | 232.2 ± 4.88        | 231.2 ± 10.30       |
| Abdominal fat          | 214,781.26 ± 7565.50| 24,764.24 ± 3112.63 | 126,762.1 ± 12637.27** | 171,691.87 ± 7204.37 | 204,538.59 ± 10,865.97** | 159,774.48 ± 6658.63 |
| Liver                  | 270,365.48 ± 8253.71| 264,972.88 ± 3943.36| 283,443.82 ± 7685.54| 262,571.47 ± 9392.70| 238,002.87 ± 6425.51| 235,675.89 ± 5742.40|
| Lungs                  | 118,498.50 ± 15,472.69| 94,800.44 ± 6201.97 | 72,416.58 ± 725660 | 95,271.092 ± 15943.46| 83,943.78 ± 1247.63 | 89,067.78 ± 6817.63 |
| Kidneys                | 64,222.43 ± 4210.62 | 52,320.42 ± 2500.44 | 55,721.72 ± 227740  | 59,531.12 ± 3155.58 | 56,560.25 ± 1821.70 | 56,51205 ± 2116.07  |
| Femur                  | 38,986.17 ± 3280.98 | 34,515.25 ± 916.01  | 37,866.95 ± 208132  | 45,917.25 ± 6570.63 | 52,231.77 ± 2007.19** | 33,434.41 ± 2449.05 |
| Dried Femur            | 18,786.86 ± 22.23   | 16,838.91 ± 1007.69 | 17,67096 ± 341.22   | 21,179.00 ± 1341.27*| 24,415.28 ± 852.49 **| 16,766.41 ± 902.75  |
| Tibia                  | 22,684.56 ± 1637.99 | 17,455.86 ± 2162.97 | 19,311.75 ± 831.75  | 21,544.21 ± 917.37  | 30,168.61 ± 1688.17 **| 21,109.35 ± 2933.98 |
| Adrenergic             | 3467.83 ± 1996.2    | 2561.80 ± 2898.7    | 2337.06 ± 237.95    | 2834.97 ± 192.60    | 2693.05 ± 1164.9    | 3066.73 ± 2119.6    |

SHAM = Sham operated rats treated with vehicle as normal control; OVX = Ovariectomized rats treated with vehicle as negative control; E2V = Ovariectomized rats treated with estradiol valerate at the dose of 1 mg/kg BW; FU 50 and 200 = Ovariectomized rats treated with F. umbellata aqueous extract at the doses of 50 and 200 mg/kg BW, respectively; MC = Ovariectomized rats treated with 7-methoxycoumarin at the dose of 1 mg/kg BW. *p < 0.05 as compared to SHAM group. **p < 0.01 as compared to OVX group. #p < 0.05 Body weight at the end of treatment compared to itself at the beginning of the treatment.
beneficial effects on lipid metabolism. This might be due to its ability to activate ERs and induce the transcription of genes involved in lipid metabolism. *F. umbellata* extract was found to contain phytoestrogens (Genistein, Biochanin A, hydroxycoumarin) which may result from the activation of gene transcription through selective binding of phytoestrogens to ERα and ERβ [34]. Such gene, in turn might display beneficial effects on lipid metabolism in postmenopausal women.

**Conclusion**

In conclusion, MC exhibited a weak estrogen activity in vitro as well as in vivo; suggesting that the estrogenic effects displayed by the whole extract is mostly due to the other phytoestrogens present in the plant. However, MC could be beneficial with regard to vaginal dryness as it showed a tissue specific effect without exposing the uterus to a potential tumorigenic growth.

**Additional files**

**Additional file 1: Table S1.** Summary of compounds separated and identified in *F. umbellata* aqueous extract by UHPLC-ESI-HRMS analysis in the negative ion mode. **Figure S1.** Microphotographs of HE-stained sections (400×) of liver, lungs, kidneys and femur from different experimental rat groups in postmenopausal-like condition after 3 weeks of treatment: SHAM = Sham operated rats treated with vehicle as normal control; O VX = Ovariectomized rats treated with vehicle as negative control; E(V) = Ovariectomized rats treated with estradiol valerate at the dose of dose 1 mg/kg BW as positive control; FU 50 and 200 = Ovariectomized rats treated with *F. umbellata* aqueous extract at the doses of 50 and 200 mg/kg BW, respectively; MC = Ovariectomized rats treated with 7-methoxycoumarin at the dose of 1 mg/kg BW. Vp = portal vein, H = Hepatocyte; S = sinusoids; A = alveol; Ba = Ateoal bag; TB = Trabeucular bone; MB = marrow bone; Mi = microgile; Ne = Neurone; Co = Cortex. G = Glomerula; Dt = Distal tube; Pr = Proximal tube. (DOXY. 797 kb)

**Abbreviations**

C-hex: Cyclo hexane; CNH: Cameroon National Herbarium; CPC: Centrifugal partition chromatography; DCM: Dichloromethane; DMEM: Dulbecco’s Modified Eagle Medium; DMSO: Dimethylsulfoxide; ER: Estrogen receptor; F: Fraction; FBS: Fetal bovine serum; FCS: Fetal calf serum; HEPES: 4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid; HPLC: High Performance Liquid Chromatography; MC: 7-methoxycoumarin; MeOH: Methanol; NMR: Nuclear magnetic resonance; PBS: Phosphate-buffered saline; PE: Proliferative effect; RPMI: Roswell Park Memorial Institute; SRB: Sulforhodamine-B

**Acknowledgments**

The present work has been done with the support from CNPq, Brazilian National Council for Scientific and Technological Development – Brazil and TWAS, the Academy of Sciences for the Developing World (Grant No. 190741/2015-5). Authors would thank the ERNI institute (http://www.erni-institute.com/) for the use of their UPLC Xevo G2 QToF apparatus. Authors would also thank Alexander von Humboldt foundation for the material support offered to Deudonné Njam.

**Funding**

The authors declare that they have not received any funding for this work.

**Availability of data and materials**

The data and materials used in this study are available upon request from the authors.

**Authors’ contributions**

ZS, and ND designed the experiments. ZS and ANN carried out the in vivo part of the study. ZS, MNCB, CJ and CC carried out the in vivo part of the study. TM and DTN carried out the phytochemical part of the study. ZS wrote the manuscript; ND. CC, CPTB and MNCB supervised the work. All authors approved the final manuscript.

**Ethics approval and consent to participate**

The housing of animals and all experiments were approved by the Cameroon Institutional National Ethic Committee, which adopted all procedures recommended by the European Union on the protection of animals used for scientific purposes (CEE Council 86/ 609; Reg. no. FWA-IRD 0001954).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Department of Life and Earth Sciences, Higher Teachers’ Training College, University of Maroua, P.O. Box 55, Maroua, Cameroon. 2. Department of Pharmaceutical Sciences, Health Sciences Centre, Federal University of Santa Catarina, CEP. Florianópolis, Santa Catarina 88040-900, Brazil. 3. Department of Applied Chemistry, Faculty of Science, University of Johannesburg, Doornfontein 2028, South Africa. 4. Institute of Chemistry of Nice, Faculty of Science, University Côte d’Azur, UMR CNRS 7272, Valrose Park, Cedex 2 Nice, France. 5. Hudson Institute of Medical Research, Clayton, VIC 3168, Australia. 6. Department of Animal Biology and Physiology, Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaounde, Cameroon.

**Received**: 26 February 2017 **Accepted**: 27 July 2017

**Published online**: 02 August 2017

**References**

1. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and Oophorectomy. J Clin Endocrinol Metab. 2005;90:3847–53.
2. Thomas F, Renaud F, Bebefice E, De Meeus T, Guegan JF. International variability of ages at menarche and menopause: patterns and main determinants. Hum Biol. 2001;72:21–90.
3. Niwo P, Onah H. Positive attitude to menopause and improved quality of life among Igbo women in Nigeria. Int J Gynecol Obstet. 2008;103:71–2.
4. Mc Clung MR. Prevention and management of osteoporosis. J Clin Endocrinol Metab. 2003;17:53–71.
5. Yang XP, Reckelhoff JF. Estrogen, hormonal replacement therapy and cardiovascular disease. Curr Opin Nephrol Hypertens. 2011;20:133–8.
6. Bhavnani BR, Strickler RC. Menopausal hormone therapy. J Obstet Gynecol can. 2005;8:137–62.
7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML. Writing Group for the Women’s health initiative investigators: risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.
8. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the million women study. Lancet. 2003;362:2419–27.
9. Skouby SO, Alazzawi F, Barlow D, Calaf-aldina erdogel PJ, Gompel A, Grazzoti A, Huidita D, Pines A, Rozenberg S, Sarnioe G, Stevenson JC. European menopause and andropause society: Climacteric medicine: european menopause and andropause society (emas) 2004/2005 position statements on per- and post-menopausal hormone replacement therapy. Maturitas. 2007;56:227–9.
10. Cheema D, Coomarasamy A, El-toukhy T. Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review. Arch Gynecol Obstet. 2007;276:463–9.
11. Boué SM, Tillghman SL, Elliott S, Zimmerman MC, Williams K, Payton-Stewart F, Miralflor AP, Howell MH, Shih BY, Carter-Wentjes CH, Segar C, Beckman BS, Wiese TE, Cleveland TE, McLachlan JA, Burow ME. Identification of the potent Phytoestrogen Glycinol in elicited soybean (Glycine max). Endocrinology. 2009;150:2446–53.

12. Arbonnier M, Arbeis et l’Académie des Sciences de l’Afrique de l’Ouest. Editions Quaê RD. 10 2-F. 78026 Versailles Cedex, France: ISBN Quaê 978–2–7592-0331-3; Museum National d’histoire Naturelle (MNHN); Service des publications scientifiques 2009; 57 Rue Cuvier, F- 75005 Paris, France; ISBN MNHN 978–2–85653-626-1. Pp 396–416.

13. Zingue S, Michel T, Tchatchou J, Magne Nde CB, Winter E, Monchot A, Andriot J, Etiope A, Godard M, Calvayrac J. Estrogenic effects of Ficus umbellata Vahl. (MORACEAE) extracts and their ability to alleviate some menopausal symptoms induced by ovariectomy in Wistar rats. J Ethnopharmacol. 2016;179:332–44.

14. De Souza LG, Renn MN, Figueroa-Villar JD. Coumarins as cholinesterase inhibitors: a review. Chem Biol Interac. 2016;254:11–23.

15. Jacquot Y, Laisi M, Cleeren A, Nonclercq D, Bermont L, Refouvelet B, Mollet J, Thévenot P, Alcaino V, Mignot J, Glardon F, Cornu É. Estrogenic activity of 4-amino-3-(2-methylbenzyl)coumarins on human breast cancer cells. Bioorg Med Chem. 2007;15:2269–82.

16. Musa MA, Cooperrud JS, Khan MO. A review of Coumarin derivatives in pharmacotherapy of breast cancer. Curr Med Chem. 2008;15:2664–79.

17. Resende FA, De Oliveira APS, De Camargo MS, Vilegas V, Varanda EA. Evaluation of estrogenic potential of flavonoids using a recombinant yeast strain and MCF7/US cell proliferation assay. Plcys One. 2013;8:7488.

18. Schillo T, Gorassi I, Longo A, Coluccia S, Gilli G. Endocrine disrupting activity in fruits and vegetables evaluated with the E-screen assay in relation to pesticide residues. J Steroid Biochem Mol Biol. 2011;127:139–46.

19. Zingue S, Magne Nde CB, Clyne C, Njamen D. Elucidation of underlying mechanisms by which Millettia macrophylla Benth induces its estrogenic activity. ISRN. 2014;2014.

20. Zingue S, Tchoumtchoua J, Ntsa DM, Sandjo LP, Cissoko J, Magne Nde CB, Winter E, Awounfack CF, Ndinteh DT, Clyne C, Njamen D, Habalabi M, Creceynoki-Pasa TB. Estrogenic and cytotoxic potentials of compounds isolated from Milletia Macrophylla Benth. (Fabaceae): towards a better understanding of its underlying mechanisms. BMC Complement Altern Med. 2016;16:765–82.

21. Drezfiet DPO, Mengue NYS, Bilanda DC, Kamareni M, Aboubakar OB-F, Dimo T, Kamcmouing P. In vivo estrogenic-like activities of Gouania Longipetala Hemsl. (Rhamnaceae) bark extracts in a post-menopause-like model of ovariectomized Wistar rats. J Ethnopharmacol. 2015;168:122–8.

22. Ammar S, Contreras MM, Belguith-Hadrich O, Bouaziz M, Segura-Carretero A. New insights into the qualitative phenolic profile of Ficus carica L. fruits and leaves from Tunisia using ultra-high-performance liquid chromatography coupled to quadrupole-time-of-flight mass spectrometry and their antioxidant activity. Rsc Adv. 2015;5:20035–50.

23. Soto AM, Lin TM, Justicia H, Silvia RM, Sonnenschein C, Colborn T, Clement C. (Eds.) Chemicals induced alterations in sexual development: The wildlife/human connection Princeton 1992. In: An "in culture" bioassay to assess the estrogenicity of xenobiotics. NJ: Princeton Scientific Publishing. p. 295–309.

24. Jiménez-Orozco FA, Rosales AAR, Vega-López A, Domínguez-López ML, García-Mondragón MJ, Maldonado-Espinoza A, Lemiñi C, Mendosa-Pathio N, Mandoki JJ. Differential effects of esculetin and daphnetin on in vitro cell proliferation and in vivo estrogenicity. Eur J Pharmacol. 2011;688:35–41.

25. Kuiper GG, Carlson B, Grondien K, Enmark E, Hagglblad J, Nilsson S, Gustafsson J-A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138:863–70.

26. Deal C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol. 2009;5:20–7.

27. Pitkin J. Alternative and complementary therapies for menopause. Menopause Int. 2012;18:20–7.

28. Silvestini G, Ballanti P, Patracchioni FR, Mocetti P, Di Grotta R, Wedard BM, Angelucci L, Benocci E. Evaluation of apoptosis and the glucocorticoid receptor in the cartilage growth plate and metaphyseal bone cells of rats after high dose treatment with corticosterone. Bone. 2000;26:33–42.

29. Baker L, Meldrum KR, Wang M, Sankula R, Vanam R, Raïsédana A, Tsai B, Hile K, Brown JW, Meldrum DR. The role of estrogen in cardiovascular disease. J Surg Res. 2003;115:326–44.

30. Parini P, Angelin B, Stave-Reus-Evers A, Freyschuss B, Eriksson H, Rudling M. Biphasic effects of the natural estrogen 17β-estradiol on hepatic cholesterol metabolism in intact female rats. Atherosclerosis. 2002;20:1817–23.

31. Ohlsson C, Hellberg N, Parini P, Vidal O, Bohlooly M, Rudling M, Lindberg MK, Wanner M, Angelin B, Gustafsson JA. Obesity and disturbed lipoprotein profile in estrogen receptor-alpha-deficient male mice. Biochem Biophys Res Commun. 2000;278:640–5.

32. Slaam K, Polat Z, Yilmaz M, Gülec M, Akinci SB. Effects of postmenopausal hormone replacement therapy on insulin resistance. Endocrine. 2002;18:211–4.

33. Fait T, Malkova J, Zivny J. Effect of hormone replacement therapy on the cardiovascular system. Cesk Gynekol. 2002;67:285–93.

34. Okamura S, Sawada Y, Sato T, Sakamoto H, Saito Y, Sumino H, Takizawa T, Kogure T, Chaichantipuy C, Higuchi Y, Ishikawa T, Sakamaki T. Pueraria mirifica phytoestrogens improve dyslipidemia in postmenopausal women probably by activating estrogen receptor subtypes. Tohoku J Exp Med. 2008;216:341–51.